Anavex Life Sciences finished running 2 studies on how blarcamesine is processed by the body and interacts with other drugs. The filing gives no findings, so it does not change the company’s outlook.
This moves Anavex’s drug research ahead, but the filing gives no study findings or patient results. Readers cannot tell from this update whether blarcamesine helps patients or creates new risks.
Follow Anavex Life Sciences Corp. (AVXL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AVXL